Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.58 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14972396 | 0.92 | TSHR (0.54) | TSHRKDM1ALMNAHSD17B10ALDH1A1 | |
| SCHEMBL14353413 | 0.89 | TSHR (0.67) | TSHRLMNAHSD17B10ALDH1A1MEN1 | |
| SCHEMBL15282914 | 0.89 | KDM1A (0.47) | TSHRKDM1AHSD17B10ALDH1A1 | |
| SCHEMBL15660197 | 0.88 | TSHR (0.57) | TSHRKDM1ALMNAHSD17B10ALDH1A1 | |
| SCHEMBL8259107 | 0.88 | TSHR (0.54) | TSHRKDM1ALMNAHSD17B10ALDH1A1 | |
| SCHEMBL1845437 | 0.86 | TSHR (0.55) | TSHRKDM1ALMNAHSD17B10ALDH1A1 | |
| SCHEMBL7350751 | 0.84 | HDAC3 (0.45) | TSHRKDM1AHSD17B10MEN1KMT2A | |
| SCHEMBL9517329 | 0.84 | TSHR (0.48) | TSHRKDM1AHSD17B10ALDH1A1MEN1 | |
| SCHEMBL9883959 | 0.83 | TSHR (0.59) | TSHRLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL15721381 | 0.83 | KDM1A (0.44) | TSHRKDM1AHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590145-B2 | Tetrahydrothiopyranopyrimidine derivatives as anti-HIV agent | SHANDONG UNIVERSITY (CN) | 2020-03-17 | — | — | US | claimed |
| US-20200031844-A1 | Tetrahydrothiopyranopyrimidine derivatives as anti-HIV agent | SHANDONG UNIVERSITY (CN) | 2020-01-30 | — | — | US | claimed |
| WO-2025092985-A1 | PHOSPHODIESTERASE 4B INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 合肥医工医药股份有限公司 | 2025-05-08 | — | — | WO | disclosed |
| US-12264169-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners (US) | 2025-04-01 | — | — | US | disclosed |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-11-02 | — | — | US | disclosed |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-11-02 | — | — | US | disclosed |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-11-02 | — | — | US | disclosed |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230024240-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-01-26 | — | — | US | disclosed |
| EP-1263756-A2 | BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | Bristol-Myers Squibb Pharma Company (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020013341-A1 | Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-31 | — | — | US | disclosed |
| WO-2001070734-A2 | BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
| US-4025630-A | Anesthesia methods using benzopyrans and esters thereof as pre-anesthesia medication | ABBOTT LABORATORIES (US) | 1977-05-24 | — | — | US | disclosed |
| US-3987190-A | Method of treating hypertension with, and compositions useful therein containing, a 4H-thieno[2,3-c][1]benzopyran or a 3H,5H-thiopyrano[2,3-c][1] | SHARPS ASSOCIATES (US) | 1976-10-19 | — | — | US | disclosed |
| US-3972880-A | TRANQUILIZER | SHARPS ASSOCIATES (US) | 1976-08-03 | — | — | US | disclosed |
| US-3960871-A | ANTIDEPRESSANT, ANALGESICS, ANTICONVULSANT ANTI-ANXIETY ACTIVITY | SHARPS ASSOCIATES (US) | 1976-06-01 | — | — | US | disclosed |
| US-3940421-A | Intermediates for the preparation of thienobenzopyrans and thiopyranobenzopyrans | ARTHUR D. LITTLE, INC. (US) | 1976-02-24 | — | — | US | disclosed |
| US-3934024-A | 1,2-DIHYDRO-5,5-DIMETHYL-10-HYDROXY-8-(3-METHYL-2-OCTYL)-3H,5H -THIOPYRANO(2,3-C)(1)BENZOPYRAN) | SHARPS ASSOCIATES (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590145-B2 | Tetrahydrothiopyranopyrimidine derivatives as anti-HIV agent | TYMP, DPYD, TPMT | TSHR 4771/4885KDM1A 3358/4885LMNA 4779/4885 |
| US-20230024240-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | TSHR 3245/4885KDM1A 2985/4885LMNA 3544/4885 |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | TSHR 3245/4885KDM1A 2985/4885LMNA 3544/4885 |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | TSHR 3245/4885KDM1A 2985/4885LMNA 3544/4885 |
| US-12264169-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | TSHR 3245/4885KDM1A 2985/4885LMNA 3544/4885 |
| US-20020013341-A1 | Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha | TNF, XPNPEP1, MMP2 | TSHR 2572/4885KDM1A 805/4885LMNA 963/4885 |
| US-20200031844-A1 | Tetrahydrothiopyranopyrimidine derivatives as anti-HIV agent | TYMP, DPYD, TPMT | TSHR 4771/4885KDM1A 3358/4885LMNA 4779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.